Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy Trials

The FDA has instituted a partial clinical hold on Aprea Therapeutics Inc's APRE clinical trials of eprenetapopt (APR-246) combined with azacitidine in its myeloid malignancy programs.
Approximately 20 patients currently receiving eprenetapopt in combination with azacitidine in the Company's myeloid malignancy programs, including the MDS, AML, and post-transplant maintenance trials, all of which have completed enrollment.
Patients who are benefiting from treatment can continue to receive study treatment. As part of the clinical hold, no additional patients can be enrolled in these trials.
Aprea intends to work closely with the FDA to analyze the data, address the specific questions raised, and seek to resolve the partial clinical hold as soon as possible.
The Company will host a webcast conference call today at 8:30 AM E.T.
Price Action: APRE shares are down 8.14% at $3.95 during the premarket session on the last check Friday.
Related content: Benzinga's Full FDA Calendar.